23 March 2021, 3:17 pm. 1 minute
On March 23, Reuters was more than a minute ahead with news that leading U.S. health agency Data Safety Monitoring Board has concerns that AstraZeneca may have included outdated information on its latest COVID-19 vaccine trial.
The news sent AstraZeneca shares down 2% in premarket trading.
Topics of Interest: Health
Type: Reuters News First
Sectors: Pharmaceuticals & Healthcare
Regions: North America
Win Types: Speed
Media Types: Text
Customer Impact: Major Global Story